September 28, 2021 -- GenScript ProBio and AskGene have signed a nonexclusive licensing agreement covering the use of GenScript ProBio's single-domain antibody (sdAb) to target an immune checkpoint target.
Specifically, the license covers the sdAb immune checkpoint target for discovery, development, and commercialization of antibody and derivative products, according to the companies. In addition, GenScript ProBio will be AskGene's preferred partner for chemistry manufacturing, and control development, as well as clinical and commercial manufacturing of the product.
The sdAb will be paired with AskGene's cytokine therapeutics technology for cancer immunotherapy and other applications, the firms said.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
